PTC Therapeutics Inc Market Cap ($4.97 Billion)
Market Cap & Net Worth: PTC Therapeutics Inc (PTCT)
PTC Therapeutics Inc market cap. PTC Therapeutics Inc (NASDAQ:PTCT) has a market capitalization of $4.97 Billion ($4.97 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3478 globally and #1244 in its home market, demonstrating a -4.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PTC Therapeutics Inc's stock price $59.97 by its total outstanding shares 82949338 (82.95 Million). Also see cash flow conversion of PTC Therapeutics Inc for how efficiently the company converts equity into cash flow.
PTC Therapeutics Inc Market Cap History (2015–2026)
PTC Therapeutics Inc market cap history from 2015 to 2026. Data shows growth from $2.69 Billion to $4.97 Billion (6.61% CAGR). Check PTCT share price today for real-time trading data and today's change.
Index Memberships
PTC Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.19% | #91 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #400 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.27% | #60 of 263 |
Weight: PTC Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PTC Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PTC Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of PTC Therapeutics Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.64x
PTC Therapeutics Inc's market cap is 3.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.23x
PTC Therapeutics Inc's market cap is 9.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $904.98 Million | $82.70 Million | -$142.11 Million | 10.94x | N/A |
| 2017 | $1.38 Billion | $194.39 Million | -$79.00 Million | 7.12x | N/A |
| 2018 | $2.85 Billion | $264.73 Million | -$128.08 Million | 10.75x | N/A |
| 2019 | $3.98 Billion | $306.98 Million | -$251.58 Million | 12.98x | N/A |
| 2020 | $5.06 Billion | $380.77 Million | -$438.16 Million | 13.30x | N/A |
| 2021 | $3.30 Billion | $538.59 Million | -$523.90 Million | 6.13x | N/A |
| 2022 | $3.17 Billion | $698.80 Million | -$559.02 Million | 4.53x | N/A |
| 2023 | $2.29 Billion | $937.82 Million | -$626.60 Million | 2.44x | N/A |
| 2024 | $3.74 Billion | $806.78 Million | -$363.30 Million | 4.64x | N/A |
| 2025 | $6.30 Billion | $1.73 Billion | $682.64 Million | 3.64x | 9.23x |
Competitor Companies of PTCT by Market Capitalization
Companies near PTC Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see PTC Therapeutics Inc assets under control for a full breakdown of the balance sheet.
Key companies related to PTC Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of PTC Therapeutics Inc (2015–2026)
Market capitalization of PTC Therapeutics Inc from 2015 to today. Between 2015 and today, PTC Therapeutics Inc's market cap moved from $2.69 Billion to $ 4.97 Billion, with a yearly change of 6.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.97 Billion | -21.05% |
| 2025 | $6.30 Billion | +68.28% |
| 2024 | $3.74 Billion | +63.79% |
| 2023 | $2.29 Billion | -27.80% |
| 2022 | $3.17 Billion | -4.17% |
| 2021 | $3.30 Billion | -34.74% |
| 2020 | $5.06 Billion | +27.07% |
| 2019 | $3.98 Billion | +39.95% |
| 2018 | $2.85 Billion | +105.76% |
| 2017 | $1.38 Billion | +52.89% |
| 2016 | $904.98 Million | -66.33% |
| 2015 | $2.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of PTC Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.97 Billion USD |
| MoneyControl | $4.97 Billion USD |
| MarketWatch | $4.97 Billion USD |
| marketcap.company | $4.97 Billion USD |
| Reuters | $4.97 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more